Raising the priorities of disease prevention  by Bonetta, L
Since joining the Global Health
Program at the Bill & Melinda Gates
Foundation, Dr Margaret Liu has
been working closely with
organizations all over the world to
facilitate their efforts in getting
vaccines made and distributed.
Bringing with her many years of
experience in vaccine development
in the industrial sector, Liu is
“excited about being at an
organization that has really helped to
catalyze a change in the whole
mentality about vaccines.”
“As a researcher trying to develop
a vaccine you hope that you can
improve peoples’ lives. It can be
frustrating to feel that the priorities
of prevention are so low on the radar
screen that with more adequate
resources and attention so much
more could be done,” says Liu. The
Bill & Melinda Gates Foundation,
currently the largest charitable
foundation in the world, has put
vaccines high on its list of priorities. 
To date the foundation has
invested over $1 billion in vaccine
development and immunization
programs. The foundation’s approach
has been to support very focused
approaches to vaccine development
and to give large sums to get the job
done. The largest donation to date
has been to the Global Fund for
Children’s Vaccines to support the
immunization of children in
developing countries through the
purchase of new and under-used
vaccines: the foundation’s pledge
stands at $750 million over the next
five years.
The foundation supports mainly
diseases that are neglected by
commercial entities. “A goodly
number of critical diseases are being
addressed, and diseases that do not
command global attention but which
are devastating in a number of
developing countries, are now
receiving attention,” says Liu. For
example, one applied research
program, currently financed by the
foundation to the tune of $40 million
is called Disease of the Most
Impoverished (DOMI). DOMI is
based at the new International
Vaccine Institute in Seoul, Korea.
The foundation’s funds will be used
for the development and
introduction of vaccines against
cholera, dysentery, and typhoid. 
Another example was the
announcement in January of a
$100 million donation to the
International Aids Vaccine Initiative
(IAVI) for the development of an
AIDS vaccine. The vaccine is one of
many AIDS vaccines being tested on
humans around the world but the
first to target the ‘A’ strain of the
HIV virus, which is prevalent in sub-
Saharan Africa.
Other major focuses of the
foundation include new delivery
systems and entities that are going to
make vaccines more broadly
available. According to Liu, there are
a number of technical challenges that
Excited: Margaret Liu, the new senior advisor
for vaccinology at the Bill & Melinda Gates
Foundation, is “excited about being at an
organization that has really helped to




Raising the priorities of disease prevention
The Bill & Melinda Gates Foundation — the software billionaire’s
charity — recently appointed Margaret Liu as its senior advisor for vacci-
nology. She tells Laura Bonetta about some of the foundation’s plans.
are encountered in the context of
vaccine efforts. These include safety,
stability at room temperature, and
removing the need for devices to
deliver a vaccine. And to increase the
number of children who are
immunized, it is important to
develop vaccines that can be
administered at birth or that
condense doses into one so that
children are not lost to follow up.
The foundation’s work is notable
not only because of the huge sums of
the donations but also because it has
helped to galvanize other public and
private sector efforts. One example
was the White House summit held in
March 2000 with the heads of the big
vaccine companies. At the meeting,
former president Clinton revealed
that he was seeking from Congress a
contribution to the Global Fund for
Children’s Vaccines but also tax
credits for companies prepared to
invest in this general area and in
other aspects of health in the
developing world.
Liu works closely with the
foundation’s grantees. She sees her
role as ‘helping grantees get what
they need to get the job done’. It
seems a perfect fit for Liu who,
before her appointment, was a
scientific advisor at the International
Vaccine Institute in Seoul and a
medical advisor for the Global Fund
for Children’s Vaccines. In addition
to overseeing the foundation’s
vaccine work, Liu assists
organizations like the World Health
Organization (WHO) with vaccine-
related activities.
Liu is also one of a handful of
advisors who evaluate proposals that
are submitted to the foundation.
While the foundation considers
unsolicited proposals, Liu cautions
that “it is better to call and talk to
someone first.” 
When asked about working with
Bill Gates, Liu praised his and his
wife’s involvement and commitment.
“They read about the issues, ask
questions, visit sites,” says Liu.
Liu joined the foundation in
October 2000. Previously, she was
vice president of vaccine research
and gene therapy at Chiron
Corporation and a senior director at
Merck & Co. And Liu spends 25% of
her time working at Transgene — a
French-based company. As
Transgene’s research interests are in
the gene therapy area, neither Liu
nor the foundation perceive a
conflict. Liu says her position at
Transgene allows her to maintain a
close contact with the whole research
and development process.
Laura Bonetta is a freelance science writer
based in the Washington DC area.
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